MAXCYTE INC
MXCTNASDAQTrading Snapshot
- Day Range
- $1.22 – $1.24
- 52-Week Range
- $0.64 – $1.87
- Volume
- $1.79B
- Avg Volume
- $1.83B
- Shares Outstanding
- 107.1M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $33M
- Last Q Revenue
- $10M
- P/E Ratio
- -3.3
- P/S Ratio
- 4.1x
- EPS (TTM)
- $-0.37
- Dividend Yield
- 0.00%
Why Investors Own MXCT
- ✓High-growth profile — revenue up +20.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MAXCYTE INC
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflowsROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership wit
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eas